Dr Reddy’s Laboratories Share Price Target 2026: Analyst Forecast, Bull & Bear Case

Dr Reddy’s Laboratories (NSE: DRREDDY) is trading at Rs 1,150 as of April 2026, against a 52-week high of undefined and a 52-week low of undefined. The analyst consensus 12-month Dr Reddy’s Laboratories share price target stands at Rs 1,350-1,550 — implying meaningful upside from current levels. This article covers the current share price, key catalysts, risks, technical support levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term share price targets.

Current Price Overview

About Dr Reddy’s Laboratories

Click Here – Get Free Investment Predictions

Dr Reddy’s Laboratories (NSE: DRREDDY) is a leading listed company in the Pharma sector with a market capitalisation of Rs 96,000 Cr. The company operates across its core business segments and is well-positioned for the Indian economic growth cycle.

Key Catalysts Driving Dr Reddy’s Laboratories Share Price

1. gRevlimid (Lenalidomide) — US Opportunity

2. Dr Reddy’s secured a settlement to launch lenalidomide (generic Revlimid) in the US with limited competition. This is a $50 million+ quarterly revenue opportunity at peak and is the largest single product catalyst for DRL in FY26-FY27.

3. Biosimilars Pipeline — Rituximab, Trastuzumab, Bevacizumab

4. Dr Reddy’s biosimilars portfolio — rituximab, trastuzumab, bevacizumab — are approved and selling in emerging markets. US biologics market entry is the next phase, starting with rituximab in FY27.

5. India Branded Formulations Recovery

6. DRL’s India formulations business grows at 10-12% — driven by Omez (pantoprazole), Stamlo (amlodipine), and Cilacar (cilnidipine). Steady branded business provides earnings floor.

7. European Generics — Profitability Recovery

8. Dr Reddy’s European generic portfolio (UK, Germany, France) is recovering profitability after years of price erosion. Newer product launches in specialty generics are improving the mix.

Key Risks to Dr Reddy’s Laboratories Share Price

US generics price erosion on base business: 

gRevlimid volumes declining faster than expected: 

FDA inspection risk at Duvvada and Srikakulam plants: 

European pricing pressure continuing: 

The 26% US reciprocal tariff on Indian goods — announced April 2, 2026 — has created a macro overhang affecting all Indian equities through FII outflows and earnings estimate revisions. Resolution of tariff uncertainty would be a meaningful positive catalyst for re-rating.

Technical Analysis and Support Levels

Dr Reddy’s Laboratories is trading at Rs 1,150 vs. a 52-week range of undefined to undefined. Key technical support is at Rs 1,080-1,220. The 200-day moving average provides medium-term guidance for trend direction.

Download the Univest iOS App or Univest Android App to track Dr Reddy’s Laboratories’s live price and get daily research insights.

Latest Quarterly Financial Performance

Track Dr Reddy’s Laboratories’s live financials on Univest Screener

Institutional Positioning — FII, DII, Promoter

Promoter holds 26.7%. FII holding is 26.4% and DII holds 14.2%. Institutional holding trends are a critical leading indicator for price direction. Rising FII holding typically precedes price recovery; declining FII signals ongoing caution. Track institutional flow changes on Univest Screener.

Dr Reddy’s Laboratories Share Price Target 2026

Subscribe to Univest Pro for Premium Stock Research and F&O Setups

Short-Term Target (3–6 Months)

Short-term support and trading range: Rs 1,080-1,220. In the near term, the stock is likely to remain in this band pending clarity on Q4 FY26 results and FY27 guidance. Any macro positive from India-US tariff negotiations would accelerate a move toward the upper end of this range.

12-Month Analyst Target

The 12-month analyst consensus for Dr Reddy’s Laboratories is Rs 1,350-1,550. The bear case — if FY27 guidance disappoints or macro headwinds intensify — is Rs 850. The bull case — on full earnings delivery and macro recovery — is Rs 1,800. These are analyst estimates based on publicly available data and may differ materially from actual price performance.

Long-Term Target (2027–2028)

For 2027-2028, analysts project Dr Reddy’s Laboratories toward the Rs 2,000-2,300 range — assuming FY27 guidance delivery and normalisation of macro headwinds. Track live targets on Univest Screener.

Conclusion

The Dr Reddy’s Laboratories share price target for 2026 is Rs 1,350-1,550 based on analyst consensus. The bear case is Rs 850 and the bull case is Rs 1,800. At Rs 1,150, Dr Reddy’s Laboratories is trading at 18x P/E with market cap of Rs 96,000 Cr. Whether this is a buy depends on your risk tolerance, investment horizon, and portfolio context. For more share price target analysis, visit 

Univest Blogs

Disclaimer: This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.

FAQs

Q1. What is Dr Reddy’s Laboratories share price target for 2026?

The 12-month analyst consensus is Rs 1,350-1,550. Bull case: Rs 1,800. Bear case: Rs 850.

Q2. Is Dr Reddy’s Laboratories a good buy at Rs 1,150?

At 18x P/E and Rs 1,150, Dr Reddy’s Laboratories offers potential recovery to Rs 1,350-1,550 over 12 months. Consult a SEBI-registered financial advisor before investing.

Q3. What are the key risks for Dr Reddy’s Laboratories?

Key risks include macro headwinds from US tariffs, sector-specific challenges, and any guidance miss in Q4 FY26 results. Monitor institutional holding trends on Univest Screener.

Q4. What is Dr Reddy’s Laboratories long-term share price target?

Long-term target for FY28 is Rs 2,000-2,300, contingent on sustained earnings delivery and macro recovery.

Recent Article

Coal India Share Price Target 2026: Analyst Forecasts, Bull & Bear Case

Bharti Airtel Share Price Target 2026: Analyst Forecasts, Bull & Bear Case

State Bank of India Share Price Target 2026: Analyst Forecasts, Bull & Bear Case

Paytm Share Price Target 2026: Analyst Forecasts, Bull & Bear Case